HYLORIS PHARMACEUTIC

HYL
Real-time Quote. Real-time  - 05/27 09:58:08 am
15.1EUR +1.07%

Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute Myeloid Leukaemia and Small Cell Lung Cancer

11/10/2021 | 01:00am
Hyloris Pharmaceuticals SA announces that it has entered into a strategic partnership with Pleco Therapeutics to develop a Plecoid? Agent, a novel combination product of chelating agents for the treatment of Acute Myeloid Leukaemia (AML) and Small Cell Lung Cancer (SCLC). The Plecoid fixed-dose combination product is a patented, innovative, clinical-stage product candidate that combines chelating agents with different characteristics and aims to detoxify the cancer promoting cellular micro-environment and improve the effectiveness of chemotherapy in patients. Previous studies demonstrate that elevated levels of toxic metals are associated with inferior survival in patients with AML. Exploratory clinical studies are currently ongoing in AML patients to evaluate the metal rebalancing effect of chelating agents administered concomitantly with chemotherapy. Under the terms of the agreement, Hyloris will provide ?1 million (automatically convertible into Pleco Therapeutics equity under certain conditions) in several tranches over time and has obtained global exclusive co-development rights and future joint commercialisation to the Pleco technology in AML and SCLC. Subject to feedback from the FDA on the feasibility of the clinical development requirements, Hyloris may commit to fund (not convertible into equity) up to an additional ?7.7 million in pre-defined R&D activities through to submission for approval in AML, plus initial exploratory development work in SCLC. Pleco will fund all activities that are outside the scope of the maximum ?7.7 million funding commitment from Hyloris. Hyloris will be eligible to receive up to 65% of the gross product margin generated worldwide in AML and SCLC. About Acute Myeloid Leukaemia (AML): AML is a type of heterogenous haematological malignancy that originates from immature white blood cells (blasts) in the bone marrow, which may be derived from either a hematopoietic stem cell or a lineage-specific progenitor cell. AML generally spreads quickly to the bloodstream and can then spread to other parts of the body including lymph nodes, spleen, central nervous system, and testicles. AML is an orphan disease and is the most common type of acute leukaemia in adults and is primarily a disease of the adulthood; the median age of newly diagnosed AML patients is around 67 years. Additionally, AML is more common in males. AML can arise de novo or secondarily either due to the progression of other diseases or due to treatment with cytotoxic agents. Datamonitor Healthcare estimates that in 2018, there were 158,400 incident cases of AML worldwide and expects that the number will increase to 169,000 by 2027.
© S&P Capital IQ 2022
Copier lien
All news about HYLORIS PHARMACEUTICALS SA
04/01
03/31
03/31
03/16
03/16